BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31779676)

  • 1. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R; Atzeni F; Sarzi Puttini P
    BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
    Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
    Ito S
    Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J; Zhou J; Zhao P; Wei J
    Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
    Mo YQ; Liang AQ; Ma JD; Chen LF; Zheng DH; Schumacher HR; Dai L
    BMC Musculoskelet Disord; 2014 Dec; 15():449. PubMed ID: 25532827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
    Ahn SS; Jung SM; Song JJ; Park YB; Park JY; Lee SW
    Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
    Laohapand C; Arromdee E; Tanwandee T
    Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary Approach to Prevent de novo Hepatitis B in Patients with Rheumatoid Arthritis.
    Watanabe R; Igarashi T; Takahashi T; Kondo H; Okazaki S; Kudo M; Ohyanagi M; Gamoh M
    Tohoku J Exp Med; 2020 Oct; 252(2):133-141. PubMed ID: 33028756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
    Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study.
    Notsumata K; Nomura Y; Tanaka A; Nomura Y; Ueda T; Sanada T; Watanabe H; Toya D
    Intern Med; 2020; 59(20):2457-2464. PubMed ID: 33055468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.